Kenneth G Hadlock

US Patent:

6692908, Feb 17, 2004

Filed:

Oct 29, 1999

Appl. No.:

09/430489

Inventors:

Steven K. H. Foung - Stanford CA
Kenneth G. Hadlock - San Francisco CA

Assignee:

Stanford University - Palo Alto CA

International Classification:

C12Q 170

US Classification:

435 5, 435339, 5303883

Abstract:

Human monoclonal antibodies binding to epitopes common to type 1 and 2 HCV are provided, as well as conformationally conserved HCV E2 2a and 2b proteins. Compositions comprising the antibodies find use in diagnosis and therapy. The antibodies recognize conformational epitopes that are conserved across multiple genotypes of HCV. Thus the antibodies have the potential to be useful in the prevention and treatment of the majority of HCV infections. A subset of the antibodies (CBH-2, CBH-5, CBH-7, CBH-8C, CBH-8E, and CBH-11) have the ability to prevent the binding of HCV E2 proteins of multiple genotypes to human CD81, a possible co-receptor for HCV infection. A subset of the antibodies (CBH-2 and CBH-5) have been shown to inhibit the binding of HCV virions (as opposed to purified E2 protein) to human CD81. A further subset of the antibodies (CBH-4D, CBH4B, CBH-8C, and CBH-9) have been shown to prevent HCV envelope mediated fusion using an HCV psuedotype system.

US Patent:

7091324, Aug 15, 2006

Filed:

Dec 1, 2000

Appl. No.:

09/728720

Inventors:

Steven K. H. Foung - Stanford CA, US
Kenneth G. Hadlock - San Francisco CA, US

Assignee:

Board of Trustees of Leland Stanford Junior University - Stanford CA

International Classification:

C07K 16/10

US Classification:

5303883, 53038815, 5303873, 5303894

Abstract:

Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.

US Patent:

7879914, Feb 1, 2011

Filed:

Sep 25, 2006

Appl. No.:

11/535001

Inventors:

Michael S. McGrath - Burlingame CA, US
Kenneth G. Hadlock - San Francisco CA, US

Assignee:

Pathlogica LLC - San Francisco CA

International Classification:

A01N 33/26
A01N 33/02
A01N 37/52
A61K 31/15
A61K 31/13
A61K 31/155

US Classification:

514674, 514664, 514639, 514634, 514632

Abstract:

Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but are not limited to, infections from human immunodeficiency viruses. These methods differ from previous methods of treatment using polyamine analogs, wherein the polyamine analogs were administered only as anti-tumor agents.

US Patent:

8114586, Feb 14, 2012

Filed:

Dec 11, 2008

Appl. No.:

12/332832

Inventors:

Steven K. H. Foung - Stanford CA, US
Kenneth G. Hadlock - San Francisco CA, US

Assignee:

Board of Trustees of Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 38/00
A61K 39/00
C07K 14/18
C07K 16/08
C07K 16/10

US Classification:

435 5, 435339, 5303883

Abstract:

Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen. Pharmaceutical compositions for prevention and treatment of HCV, comprising one or more the monoclonal antibodies, are provided.

US Patent:

8445540, May 21, 2013

Filed:

Mar 10, 2008

Appl. No.:

12/045623

Inventors:

Kenneth G. Hadlock - San Francisco CA, US
Hope Lancero - Palo Alto CA, US
Stephanie Yu - San Francisco CA, US
Hien Kim Do - Palo Alto CA, US

Assignee:

Pathologica LLC - San Francisco CA

International Classification:

A61K 31/165

US Classification:

514623

Abstract:

The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.

US Patent:

20060160087, Jul 20, 2006

Filed:

Jan 30, 2004

Appl. No.:

10/544059

Inventors:

Michael McGrath - Burlingame CA, US
Kenneth Hadlock - San Francisco CA, US

International Classification:

C12Q 1/68
G01N 33/567

US Classification:

435006000, 435007200

Abstract:

The invention provides methods of monitoring amyotrophic lateral sclerosis (ALS) disease development or progression and monitoring an ALS therapy in an individual by determining the presence or absence of Herv-K/HML-2 expression in a biological sample from the individual. The invention is also directed to methods for aiding diagnosis of ALS by determining expression of Herv-K/HML-2 in a biological sample from the individual. The invention is also directed to methods of reducing Herv-K/HML-2 expression in infected cells and individuals. The invention includes reagents for use in these methods.

US Patent:

20060188511, Aug 24, 2006

Filed:

Oct 5, 2004

Appl. No.:

10/958624

Inventors:

Steven Foung - Stanford CA, US
Kenneth Hadlock - San Francisco CA, US
Zhenyong Keck - Redwood City CA, US

International Classification:

A61K 39/42

US Classification:

424161100

Abstract:

Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen. Pharmaceutical compositions for prevention and treatment of HCV, comprising one or more the monoclonal antibodies, are provided.

US Patent:

20070032635, Feb 8, 2007

Filed:

Aug 15, 2006

Appl. No.:

11/504974

Inventors:

Steven Foung - Stanford CA, US
Kenneth Hadlock - San Francisco CA, US

International Classification:

C07H 21/04
C07K 14/00
C07K 16/00
A61K 38/00
C07K 17/00
C07K 2/00
C07K 4/00
C07K 5/00
C07K 7/00

US Classification:

530300000, 536023720

Abstract:

Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.